JCR Pharmaceuticals Co Ltd 2024 SR
The report highlights JCR Pharmaceuticals' commitment to developing treatments for rare and ultra-rare diseases, particularly through its proprietary J-Brain Cargo technology which crosses the blood-brain barrier. It details the global progress of its lead therapy, JR-141 (Izcargo), and the expansion of its pipeline into gene therapy. The company outlines its sustainability governance, including the establishment of advisory and environmental committees, and reports on key ESG initiatives such as reducing CO2 emissions through waste recycling and promoting diversity in talent development.
Company: JCR Pharmaceuticals Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: SR
Pages: 12
JCR Pharmaceuticals Co Ltd
Report
The report highlights JCR Pharmaceuticals' commitment to developing treatments for rare and ultra-rare diseases, particularly through its proprietary J-Brain Cargo technology which crosses the blood-brain barrier. It details the global progress of its lead therapy, JR-141 (Izcargo), and the expansion of its pipeline into gene therapy. The company outlines its sustainability governance, including the establishment of advisory and environmental committees, and reports on key ESG initiatives such as reducing CO2 emissions through waste recycling and promoting diversity in talent development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees